You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
白雲山(00874.HK)分公司獲得藥品補充申請批件
格隆匯 03-03 18:22

格隆匯3月3日丨白雲山(00874.HK)發佈公告,2020年3月3日,公司分公司廣州白雲山醫藥集團股份有限公司白雲山製藥總廠收到廣東省藥品監督管理局核准簽發的羧甲司坦口服溶液《藥品補充申請批件》。

羧甲司坦口服溶液適用於治療慢性支氣管炎、支氣管哮喘等疾病引起的痰液粘稠、咳痰困難患者。在國家藥品監督管理局網站查詢,羧甲司坦口服溶液共有12個批准文號。

根據米內網數據顯示,2018年羧甲司坦口服溶液在中國城市公立醫院、縣級公立醫院的銷售總額為人民幣1.78億元。除此之外,公司無法從公開渠道獲悉其他生產企業此藥品的生產或銷售數據。2018年度白雲山製藥總廠上述兩種規格藥品的銷售收入為人民幣3,040.32萬元,約佔白雲山製藥總廠2018年度的營業收入的0.92%,約佔公司2018年度的營業收入的0.07%。

白雲山製藥總廠獲得廣東省藥品監督管理局批件,延長了上述產品有效期,有利於提高產品的市場競爭力。由於醫藥產品具有高科技、高風險、高附加值的特點,各類投產後的藥品未來具體銷售情況可能受到市場環境變化等因素,故產品未來發展具有較大不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account